2025年美国临床肿瘤学年会（ASCO 2025）将于5月30日-6月3日在美国芝加哥举行。ASCO官网已公布了大会日程，本刊整理了中国学者被收录的妇科肿瘤研究内容，供读者参考。
2025年美国临床肿瘤学年会（ASCO 2025）将于5月30日-6月3日在美国芝加哥举行。ASCO官网已公布了大会日程，本刊整理了中国学者被收录的妇科肿瘤研究内容，供读者参考。
口头报告专场
Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer:The PHENIX trial
宫颈癌前哨淋巴结活检vs盆腔淋巴结清扫术对比：PHENIX试验
汇报者：刘继红丨中山大学肿瘤防治中心
摘要号：LBA5501
Benmelstobart plus carboplatin/paclitaxel with or without anlotinib，followed by maintenance benmelstobart with or without anlotinib，as first-line treatment for advanced or recurrent endometrial cancer:A randomized，open-label，phase II trial.
贝莫苏拜单抗联合卡铂/紫杉醇±安罗替尼治疗后，序贯贝莫苏拜单抗±安罗替尼维持治疗用于晚期或复发性子宫内膜癌一线治疗：一项随机、开放标签、II期临床试验
汇报者：陈晓军丨上海市第十人民医院
摘要号：5508
快速口头摘要专场
Cadonilimab plus platinum-based chemotherapy±bevacizumab for persistent，recurrent，or metastatic cervical cancer:Subgroup analyses of COMPASSION-16.
卡度尼利单抗联合含铂化疗±贝伐珠单抗治疗持续性、复发性或转移性宫颈癌：COMPASSION-16亚组分析
汇报者：吴小华丨复旦大学附属肿瘤医院
摘要号：5509
Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB，recurrent or persistent cervical squamous cell carcinoma:A multi-center，randomized，double-blind，and controlled study.
尼妥珠单抗联合化疗用于IVB期、复发性或持续性宫颈鳞癌一线治疗：一项多中心、随机、双盲、对照研究
汇报者：Zexuan Liu丨中国医学科学院肿瘤医院
摘要号：5510
Safety and efficacy of BAT8006，a folate receptorα(FRα)antibody drug conjugate，in patients with platinum-resistant ovarian cancer:Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.
叶酸受体α（FRα）抗体药物偶联物BAT8006用于铂耐药卵巢癌患者的安全性和有效性：BAT-8006-001-CR试验剂量优化/扩展队列更新
汇报者：张松灵丨吉林大学第一医院
摘要号：5517
壁报
Preliminary results of ZG005，a bispecific antibody targeting PD-1 and TIGIT，in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.
PD-1/TIGIT双特异性抗体ZG005联合化疗±贝伐珠单抗作为晚期宫颈癌一线治疗的初步结果
汇报者：楼寒梅丨浙江省肿瘤医院
摘要号：5529
Preliminary results of ZG005，a bispecific antibody targeting PD-1 and TIGIT，as monotherapy in patients with advanced cervical cancer.
PD-1/TIGIT双特异性抗体ZG005单药治疗晚期宫颈癌患者的初步结果
汇报者：楼寒梅丨浙江省肿瘤医院
摘要号：5528
A phase II study of tumor microenvironment profiling at single cell level in patients with locally advanced cervical cancer(LACC)treated with immunotherapy combined with concurrent chemoradiotherapy(CICRT).
接受免疫治疗联合同步放化疗的局部晚期宫颈癌的单细胞水平肿瘤微环境分析II期研究
汇报者：Yuhan Sheng丨华中科技大学同济医学院附属协和医院
摘要号：5518
Effects of surgery on the prognosis of patients with locally advanced vulva cancer:A retrospective study of the SEER database and a Chinese multicentre registry.
手术对局部晚期外阴癌患者预后的影响：基于SEER数据库和中国多中心登记库的回顾性研究
汇报者：徐沁丨福建省肿瘤医院
摘要号：5616
SHR-A1811 in patients(pts)with HER2-expressing advanced gynecological cancers(Gynecol C):A phase 2 study.
SHR-A1811治疗HER2表达晚期妇科癌症患者（Gynecol C）的II期研究
汇报者：孔北华丨山东大学齐鲁医院
摘要号：5612
Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer:A single-arm，prospective phase II trial.
新辅助帕米帕利治疗新诊断晚期卵巢癌患者：一项单臂前瞻性II期试验
汇报者：Jing Liu丨福建省肿瘤医院
摘要号：5593
Clinicopathological and prognostic characteristics of gastric-type endocervical adenocarcinoma:A single-center retrospective study.
宫颈胃型腺癌的临床病理学和预后特征：单中心回顾性研究。
汇报者：Yang Liu丨复旦大学附属妇产科医院
摘要号：5525
Induction cadonilimab combined with chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer:A multicenter，single-arm，phase II trial.
卡度尼利单抗联合化疗诱导后序贯放化疗治疗局部晚期宫颈癌：一项多中心、单臂、II期临床试验
汇报者：Lin Ding丨中山大学孙逸仙纪念医院
摘要号：5530
Safety and effectiveness of fuzuloparib in patients with ovarian cancer:A nationwide，multicenter，prospective real-world study.
卵巢癌患者使用氟唑帕利的安全性和有效性：一项全国性、多中心、前瞻性真实世界研究
汇报者：高庆蕾丨华中科技大学同济医学院附属同济医院
摘要号：5572
Analysis of serous carcinoma subgroup in FRUSICA-1:Fruquintinib plus sintilimab in treated advanced endometrial cancer(EMC)patients(pts)with pMMR status.
FRUSICA-1试验中的浆液性癌亚组分析：呋喹替尼联合信迪利单抗治疗pMMR型晚期子宫内膜癌患者
汇报者：吴小华丨复旦大学附属肿瘤医院
摘要号：5596
京公网安备 11010502033352号